ByJohn A
Wegovy vs Zepbound: Differences in Mechanism, Evidence, and Expected Results
Wegovy and Zepbound treat the same condition through different biology. Wegovy is semaglutide, which acts on the GLP-1 receptor alone. Zepbound is tirzepatide, which acts on both the GLP-1 and GIP receptors. In their separate registration trials, semaglutide produced roughly 15 percent mean body weight reduction and tirzepatide produced roughly 21 percent at the highest dose. Those trials were never run head to head against each other, which matters when reading the numbers.
The mechanical difference is one receptor versus two
Semaglutide mimics glucagon-like peptide-1, a hormone the gut releases after eating. It slows gastric emptying, increases satiety signaling in the brain, and improves glucose-dependent insulin release. That single-pathway action is well characterized and has been in clinical use for type 2 diabetes since long before the weight management indication existed.
Tirzepatide adds a second target: glucose-dependent insulinotropic polypeptide, or GIP. GIP is also an incretin hormone, and combining the two receptors appears to produce a larger metabolic effect than engaging GLP-1 alone. The mechanism behind that additive benefit is still being characterized. What is established is that the dual agonist produced larger average weight reductions in trials than single-agonist semaglutide did in its own.
Both are once-weekly subcutaneous injections. Both require dose escalation over several months rather than starting at a therapeutic dose. Neither works without sustained use, and both show weight regain when discontinued.
What the trials actually measured
STEP-1 studied semaglutide 2.4 mg in adults with overweight or obesity without diabetes over 68 weeks. Participants on the active drug lost about 14.9 percent of body weight against about 2.4 percent for placebo.
SURMOUNT-1 studied tirzepatide over 72 weeks in a broadly similar population. Weight reduction was about 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, against about 3.1 percent for placebo.
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Receptor target | GLP-1 | GLP-1 and GIP |
| Registration trial | STEP-1, 68 weeks | SURMOUNT-1, 72 weeks |
| Mean weight reduction | About 14.9% | About 15.0% to 20.9% by dose |
| Placebo comparator | About 2.4% | About 3.1% |
| Administration | Weekly injection | Weekly injection |
| Titration | Stepwise over months | Stepwise over months |
Why the numbers are not a fair race
The single most common error in comparisons of these two drugs is lining up 14.9 percent against 20.9 percent and calling it a result. Those figures come from different trials, run by different sponsors, with different enrollment criteria, different durations, and different placebo responses. A cross-trial comparison suggests a direction. It does not establish a margin.
The direction does appear real. A dedicated head-to-head trial, SURMOUNT-5, was subsequently run to compare tirzepatide against semaglutide directly, and its published analyses continue to report greater average reduction for tirzepatide. That is a stronger form of evidence than lining up two separate trials, because it removes the differences in population and protocol that make cross-trial arithmetic unreliable.
Even so, averages describe populations, not people. Trial cohorts show wide individual spread, with some participants far exceeding the mean and others responding barely at all. Neither average predicts what any specific person will experience, and a person who tolerates one molecule poorly may do well on the other regardless of which produced the larger group mean.
Expected results in practice
Two things shift real-world outcomes away from trial figures. The first is adherence. Trial participants received structured lifestyle support and close follow-up. The second is dose. Both drugs show dose-dependent effects, and many people stop escalating below the maximum studied dose because of side effects, cost, or supply.
Someone who reaches and maintains the top studied dose of either drug is in roughly the territory the trials describe. Someone who stalls at a middle dose should expect proportionally less. This is where access and continuity matter more than the choice between molecules. Cost interruptions, insurance denials, and supply gaps all pull results downward, which is why the practical route to the medication deserves as much attention as the pharmacology. Supervised telehealth providers such as FormBlends publish transparent cash pricing precisely because unpredictable cost is one of the most common reasons people stop treatment early.
Titration is part of the result
Neither drug starts at its studied dose. Both begin low and step up over a period of months, and that schedule exists to limit gastrointestinal effects rather than to delay benefit. People often read early weeks as a verdict on whether the drug is working, when the starting dose was never expected to deliver the trial outcome.
This has a practical consequence for comparing the two. A person four weeks into either drug is not experiencing the version of it that produced the published figures. Judging tolerance early is reasonable. Judging efficacy early is not, and switching on the basis of a low-dose response often restarts the same escalation from the beginning.
Safety profile is broadly similar
Both carry a boxed warning for thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both commonly cause gastrointestinal effects, chiefly nausea, diarrhea, vomiting, and constipation, most pronounced during dose escalation.
Compounded versions of either molecule are not FDA-approved products. They are prepared by compounding pharmacies and have not been through the approval process that produced the trial evidence described above. That is a factual distinction about the product, and it is worth understanding before treating compounded and brand medication as interchangeable.
For anyone weighing the two molecules, the practical question of where to obtain either one tends to shape the experience as much as the trial numbers do. The providers in this space are easy to name and easy to line up: Ro and Hims and Hers sell medication inside a monthly membership, LillyDirect and NovoCare route patients to the drugmakers’ own self-pay programs, and clinics such as HealthRX keep a Wegovy vs Zepbound breakdown online with pricing attached to each option. Comparing a few of them shows quickly which route a person can afford to stay on long enough for the mechanism to matter.
Frequently asked questions
Is Zepbound simply a stronger version of Wegovy?
No. It is a different molecule with an additional receptor target, not a higher dose of the same drug. The dual mechanism produced larger average reductions in its trial, but the drugs are not interchangeable on a dose-for-dose basis.
Can the trial percentages be compared directly?
Not reliably. STEP-1 and SURMOUNT-1 were separate studies with different populations, durations, and placebo responses. They indicate a direction of effect rather than a precise margin between the two drugs.
Does either drug work without lifestyle change?
Both trials paired medication with lifestyle intervention, so the reported figures reflect that combination. Neither drug was studied as a standalone treatment, and the published results should not be read as medication-only outcomes.
What happens after stopping?
Both show substantial weight regain following discontinuation. These are treatments for an ongoing condition rather than a fixed course, which is why long-term affordability tends to determine long-term results.
Which one produces fewer side effects?
Neither has a clearly gentler profile. Both produce mainly gastrointestinal effects concentrated during escalation, and individual tolerance varies enough that it cannot be predicted from the drug choice alone.
